Rosen, National Investors Advisory, Regeneron Pharmaceuticals, Inc. It encourages investors to wait for advice before they get the necessary time frame in the securities section

NEW YORK, NY–(The News File Corporation – January 18, 2025) – why: Rosen Law Firm, a global investor rights law firm, represents Regeneron (NASDAQ:) Pharmaceuticals, Inc. (NASDAQ: REGN ) between November 2, 2023 and October 30, 2024, Regeneron (NASDAQ: ) Pharmaceuticals, Inc. (NASDAQ: REGN ) announced that it has filed a class action lawsuit on behalf of Purchases. , both dates inclusive (“Class Period”). A class action lawsuit has already been filed. If you want to serve as lead plaintiff, you must move the court After 10 March 2025.

So what? If you purchase Regeneron Securities during the Class Period, you may receive compensation through a contingent payment arrangement without paying any out-of-pocket fees or expenses.

What to do next: To join a Regeneron class action, go to or call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for class action information. A class action lawsuit has already been filed. If you want to serve as lead plaintiff, you must move the court After 10 March 2025. A lead plaintiff is a representative party who conducts litigation on behalf of other class members.

Why the Rose Rule? We encourage investors to select a qualified advisor with a track record of success in a leadership role. Oftentimes, the organizations that issue the ads don’t have comparable experience, resources, or any meaningful peer recognition. Be wise when choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class actions and shareholder derivative litigation. Rosen Law Firm brought the largest securities class action against a Chinese company at the time. Rosen Law Firm is rated Class 1 by ISS Securities. Action (WA:) Services in 2017 for the securities division of the action settlement number. The firm has been ranked in the top 4 every year since 2013 and has returned hundreds of millions of dollars to investors. In the year In 2019 alone, the company raised over $438 million for investors. In the year In 2020, founding partner Lawrence Rosen was named a Titan of the Plaintiffs Bar by Law360. Many of the firm’s lawyers are accredited by Laudragon and Super Lawyers.

Details of the case:- According to the lawsuit, during the class period, the defendants made false and misleading statements and/or failed to disclose: (1) Regeneron made credit card payments to distributors when the distributors did not pay customers of Eylea, Regeneron’s flagship products; , to use an additional credit card; (2) These fees subsidize the price customers paid when using credit cards to purchase Eylea. (3) as a result, Regeneron proposed a price agreement that would reduce the selling price of Eylea; (4) Regeneron’s price discounts provided a competitive advantage when purchasing anti-vascular endothelial growth factor (“anti-VEGF”) drugs because retina practices were price sensitive when using credit cards. (5) As a result of the above, Regeneron misleadingly reported that Eylea sales increased; (6) By failing to report credit card payments as rebates, Regeneron reported Average Selling Price (“ASP”) to federal agencies, thereby violating the False Claims Act; and (7) for the reasons set forth above, Defendants’ positive statements about Regeneron’s business, operations and prospects were materially misleading and/or lacked a reasonable basis. Investors were harmed, the lawsuit says, when the correct listings entered the market.

To join a Regeneron class action, go to or call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for class action information.

No class confirmed. Unless a unit is confirmed, you will not be represented by a consultant unless you have booked one. You can choose the advice of your choice. You can also remain a member of a class you are not in and do nothing at this point. An investor’s ability to participate in any future recovery is not dependent on serving as a lead plaintiff.

Follow us for updates on LinkedIn, Twitter, or Facebook (NASDAQ).

Notice of attorney. Previous results do not guarantee the same result.

————————————-

To view the source of this press release, please visit https://www.newsfilecorp.com/release/237656.